52 results about "IMMUNE IMBALANCE" patented technology

The invention relates to a novel application of animal bifidobacterium subsp. Lactis BGI-N3, in particular to an application of the animal bifidobacterium subsp. Lactis BGI-N3 in preparation of a preparation for relieving skin allergy. The invention finds that the bifidobacterium animalis subsp. Lactis BGI-N3 has a very remarkable effect in the aspect of relieving skin allergy, and the effect is specifically shown as follows: in an atopic dermatitis animal model, the dermatitis score, scratching times and percutaneous water loss are remarkably reduced, and the atopic dermatitis skin tissue damage condition is relieved; the immune organ edema condition is improved, the levels of Th2 type cell factors and inflammatory factors IL-6, TNF-alpha and IFN-gamma related to dermatitis are reduced, and the immune balance of the body is recovered; expression of fibroin and endothelial protein in skin tissue is improved, and the skin barrier is repaired; the level of antibacterial peptide in skin tissues is recovered, and the antibacterial activity of the skin is enhanced. Meanwhile, compared with a traditional chemical medicine for treating atopic dermatitis, the animal bifidobacterium subsp. Lactis BGI-N3 has no side effects such as weight loss, immune organ atrophy, immune imbalance and the like.

The invention relates to preparation of a medicinal and edible active ingredient composition with an immune regulation function. According to the composition, main effective components in medicinal and edible plants including fructus arctii and codonopsis pilosula are adopted, and arctigenin and codonopsis pilosula polysaccharide are combined, so that an immune regulation function is realized. Each experimental index of the composition is superior to that of the single action of the effective components, and the comprehensive effect of the synergistic effect is embodied. The composition is derived from effective components of traditional Chinese medicines with homology of medicine and food, can be applied to susceptible people with immune imbalance, can improve inflammatory response of swollen sore throat and the like, and has wide health-care function development and application prospects.

The invention relates to 2 '-fucosyllactose, in particular to application of the 2'-fucosyllactose to preparation of immune balance drugs or food. The immune balance comprises regulation and control of the ratio of Th17 cells to Treg cells of Th17 / Treg immune imbalance offspring activated by maternal immune or induced by virus infection; according to the application disclosed by the invention, the fact that filial generations generated after the maternal body of a mammal generates immune reaction activation can regulate and control the proportion of Th17 and Treg cells through the influence of 2 '-fucosyllactose on intestinal flora is found, so that Th17 and Treg immune balance is realized; in addition, social and cognitive disorders and repetitive behaviors related to filial generation autism induced by Th17 / Treg immune imbalance can be improved.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention belongs to the technical field of biological medicines, and particularly relates to nasal temperature-sensitive hydrogel with immunoregulation and anti-inflammatory functions as well as a preparation method and application of the nasal temperature-sensitive hydrogel. The preparation method of the nasal temperature-sensitive hydrogel with the immunoregulation and anti-inflammatory functions comprises the following steps: preparation of hydroxybutyl chitosan (HBC), preparation of levodopa-hydroxybutyl chitosan (LHBC), and preparation of CELHBC composite hydrogel. The novel temperature-sensitive hydrogel composite material of the composite hydrogel loaded with the chlorella / exosome can be used for the focus position of allergic rhinitis, and enrichment and retention of active ingredients are achieved; the chlorella is combined with the exosome, so that the inflammatory response of nasal mucosa can be relieved, the damaged nasal mucosa can be repaired, and the immune imbalance of Th1 / Th2 cells can be reversed, thereby improving the treatment effect of allergic rhinitis.

The invention provides in-situ forming fluid bionic hydrogel as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The invention provides an injectable GelSSO / PDA (at) SDF fluid bionic niche, after in-situ photo-crosslinking, preferential and sustained release of PDA (at) SDF NPs initiates early signal amplification, which recruits EPCs and MSCs through an SDF-1 alpha / CXCR4 axis, promotes activation of the angiogenic vascular niche through an AKT signal, and repolarizes macrophages to a regenerated M2 phenotype. Subsequently, the gradual degradation of the bionic niche triggers the stable release of SSO, and the later signal is further amplified to form an osteogenic niche with transcriptional activity, thereby maintaining the MAPK / ERK-mediated MSCs osteogenic differentiation. The fluid bionic niche can form a niche conforming to defects through photopolymerization, the local immune imbalance and endogenous progenitor cell recruitment are corrected in the early stage, then formation of new vessels and lamellar bones is promoted, and finally vascularization regeneration of diabetic skull defects is achieved.

The invention belongs to the technical field of biology, and discloses an anti-human CD38 antibody and application thereof. The anti-human CD38 antibody disclosed by the invention can be specifically combined with human CD38 protein, and the combination is stable. The antibody is coupled with an adsorption column to pertinently adsorb B cells in blood, so that the level of pathogenic factors can be quickly reduced, and abnormally activated or pathogenic B cells in circulation and pathogenic factors such as antibodies, cell factors and the like generated by the abnormally activated or pathogenic B cells are quickly reduced, thereby quickly relieving symptoms. The B cells can be cleared relatively specifically, and the influence on other cells is reduced. The traditional Chinese medicine composition has the advantages that time is bought for other treatments, in the acute attack or serious stage of diseases, illness state stabilization is facilitated, favorable conditions are created for subsequent immunoregulation treatment or other targeted treatment, immune imbalance can be improved, the imbalance state of an immune system can be adjusted, and immune homeostasis can be recovered. When necessary, adsorption can be repeatedly carried out to maintain the treatment effect, and the safety is high.

The invention relates to the technical field of probiotics, in particular to an application of a probiotic (Bifidobacterium longum) in allergic asthma (preventing, relieving or treating allergic asthma). The invention relates to an application of probiotics in allergic asthma, in particular to an application of the probiotics in inhibiting a PI3K / AKT / NF-kappa B signal channel. According to the probiotics disclosed by the invention, activation of a PI3K / AKT / NF-kappa B signal channel is specifically inhibited, immune imbalance is regulated and controlled from the source, and Th2 type immune response is effectively inhibited. Specifically, the total IgE level in serum and the expression of Th2 type cytokines such as IL-4, IL-5 and IL-13 are remarkably reduced, the inflammatory response of the airway mainly caused by eosinophilic granulocyte infiltration is relieved, and the airway high reactivity and airway remodeling are effectively improved. The invention provides a novel intervention strategy which is clear in mechanism, high in safety and capable of treating both symptoms and root causes according to the intestine-lung axis theory, and has a wide application prospect in the aspect of treating allergic asthma.

The application belongs to the technical field of biological medicine, and particularly relates to application of an active component of chamomile in preparation of an asthma treatment preparation. The chamomile active component is prepared by the following method: chamomile is subjected to reflux extraction with ethanol as an extraction solvent to obtain an extract; the extract is purified, eluted with water and ethanol in sequence, and the eluate of ethanol is collected and dried to obtain the chamomile active component. The chamomile active component provided in the application can regulate autophagy and apoptosis through multiple targets, inhibit airway inflammation, and improve immune imbalance, and can not only effectively relieve asthma symptoms, but also reduce airway epithelial damage and inhibit airway remodeling, thereby overcoming the defects of existing drugs, such as large side effects, limited efficacy on severe and hormone-resistant asthma patients, and difficulty in reversing airway damage. The active component is derived from a natural plant, is safe, and has a good application prospect in preparation of asthma treatment drugs.

The invention relates to Witzia ciliaris capable of regulating mood health and relieving anxiety and an application of the Witzia ciliaris. The Witzia ciliaris is separated from a healthy human excrement sample. According to the present invention, the Witzia ciliata KY009 can regulate the levels of 5-hydroxytryptamine, brain-derived neurotrophic factors and cortisol so as to provide the anti-depression effect, can significantly reduce the contents of hippocampal proinflammatory factors such as IL-1beta, IL-6 and IFN-alpha, and has the neuroinflammation inhibition activity. The strain and the composition thereof can be used for preparing medicines for treating depression, functional foods for relieving depressive mood and health-care products for improving mood, play a therapeutic role by correcting immune imbalance state of a body and regulating neuroinflammation, and provide a new microbial intervention strategy for treatment of depression and related mood disorders.

The invention provides a polypeptide and application thereof in preparation of an immunomodulatory product. It is found that the polypeptide with the amino acid sequence shown as SEQ ID NO: 1 can significantly improve the secretion amount of macrophage inflammatory factors and the ROS generation amount, enhance immunity, significantly reduce the influence of LPS on macrophage NO release and inflammatory factor secretion and repair immune imbalance caused by excessive inflammation, and it is indicated that the polypeptide has excellent immunoregulation activity and can be used for preparing immunomodulatory drugs for treating the macrophage NO release and inflammatory factor secretion. In other words, the polypeptide is suitable for preparing products for enhancing immunity, immunoregulation products and drugs for preventing and / or treating immune diseases.

The invention belongs to the technical field of biology, and discloses an anti-human CD19 single-chain antibody and application. The anti-human CD19 single-chain antibody disclosed by the invention can be specifically combined with human CD19 protein, and the combination is stable. The single-chain antibody is coupled with an adsorption column, B cells in blood are adsorbed in a targeted manner, the pathogenic factor level can be rapidly reduced, abnormally activated or pathogenic B cells in circulation and pathogenic factors such as antibodies and cell factors generated by the abnormally activated or pathogenic B cells are rapidly reduced, and therefore symptoms are rapidly relieved. The B cells can be cleared relatively specifically, and the influence on other cells is reduced. The traditional Chinese medicine composition strives for time for other treatments, is helpful for stabilizing the illness state in the acute attack or serious stage of the disease, and creates favorable conditions for subsequent immunoregulation treatment or other targeted treatments. The immune imbalance can be improved, the imbalance state of the immune system can be adjusted, and the immune homeostasis can be recovered. When necessary, adsorption can be repeatedly carried out to maintain the treatment effect, and the safety is high.

This invention provides synthetic immodulin peptides and related compositions and methods. The peptides of this invention exhibit new and surprising biological activities, such as the expansion of specified differentiated mammalian lineages from precursor cell populations which play important roles in post-apoptotic clearance, autoimmunity, targeted vaccination, cancer and trauma, by contacting mammalian cells with the synthetic peptides. Furthermore, the peptides of the invention can be made significantly more potent by each of a series of modifications described in the invention, including a carboxyterminal tripeptide extension to the canonical immodulin core sequence, other peptide extensions with kinase-inhibiting and other domains, substitution with modified amino acids, conjugation to certain bioactive small molecules, complexation to metals or glycosaminoglycans, and co-administration with helper molecules. The invention also teaches compositions and methods for enhancing previously disclosed uses of immodulin peptides to boost the efficacy of immodulin peptides in trauma, immune imbalance, cancer and other medically relevant conditions.

The invention relates to the field of biological medicines, and discloses application of an OGG1 micromolecule agonist in preparation of a medicine for treating liver inflammatory diseases. According to the micromolecule TH10785, by activating the beta, delta-lyase activity of DNA repair enzyme OGG1, the oxidized DNA repair capacity is remarkably enhanced, ROS accumulation in liver cells is reduced, NF-kappa B signal channel activation and proinflammatory factor release are inhibited, and therefore liver inflammation and fibrosis are effectively relieved. Meanwhile, the medicine can inhibit the activation of B cells and the formation of plasma cells, finally reduces the generation of autoimmune antibodies, and improves the immune imbalance state of autoimmune hepatitis. The invention provides an innovative treatment strategy based on OGG1 enzyme function amplification, and a new pharmacological approach is provided for treatment of chronic liver diseases and immunological liver injury.

The invention discloses a traditional Chinese medicine composition for improving related symptoms of ovarian insufficiency and application of the traditional Chinese medicine composition, and belongs to the field of traditional Chinese medicines. The method mainly comprises the following steps: selecting 6-15 parts by weight of artemisia apiacea, 6-12 parts by weight of scutellaria baicalensis, 9-18 parts by weight of morinda officinalis, 15-30 parts by weight of light wheat, 12-24 parts by weight of prepared rehmannia root, 9-18 parts by weight of lily, 3-9 parts by weight of prepared common monkshood daughter root and 15-30 parts by weight of calcined oyster shell, cleaning the raw material medicines to remove non-medicinal parts and impurities, properly crushing the calcined oyster shell to facilitate dissolution of effective components, and drying to obtain the traditional Chinese medicine composition. Soaking the cooked radix aconiti lateralis praeparata slices in saline water, and cooking to reduce the toxicity for later use; through scientific compatibility of traditional Chinese medicines such as artemisia apiacea, scutellaria baicalensis and morinda officinalis, and by following the treatment method of clearing the upper part and warming the lower part and traffic heart and kidney, comprehensive intervention is realized, so that vasomotor symptoms such as hectic fever, night sweat and the like can be remarkably improved, sleep disorders such as insomnia, upset and the like can be relieved, osteoporosis can be prevented and improved through the effects of tonifying kidney and strengthening bone, and meanwhile, the immune imbalance state can be regulated.

The invention relates to the technical field of recombinant bacillus calmette guerin vaccines, in particular to a gene knockout attenuated granulysin / IL-12 recombinant plasmid, a recombinant bacillus calmette guerin and application. The nucleotide sequence of the recombinant plasmid is shown as SEQ ID NO: 1, and the recombinant plasmid contains IL-12 and GLS gene segments. The gene knockout attenuated granulysin / IL-12 recombinant bacillus calmette guerin vaccine contains the recombinant plasmid disclosed by the invention. The TrpD gene of the BCG is knocked out and is combined with an IL-12 / GLS double-gene eukaryotic expression system to construct a recombinant BCG strain, so that the dual functions of effect enhancement and toxicity reduction are realized, and the BCG strain is used for treating bladder cancer. The TrpD gene of the BCG is knocked out, the toxicity of the BCG is reduced, the disseminated infection risk is reduced, and the safety is improved; th1 immune imbalance is corrected, the anti-tumor effect is enhanced, tumor microenvironment Th1 type immune remodeling is induced through IL-12, and the anti-tumor effect is enhanced; a double-gene expression system is adopted, synergistic interaction is achieved, an IL-12 / GLS double-gene expression system is integrated, IL-12 regulates Th1 unbalance, and GLS directly induces tumor cell apoptosis.

The present invention relates to a traditional Chinese medicine composition, an oral liquid for treating rhinitis, and a preparation method and application thereof. The traditional Chinese medicine composition comprises the following components in parts by weight: stir-fried Xanthii Fructus 10-45 parts, Magnoliae Flos 10-45 parts, Angelicae Dahuricae Radix 10-30 parts, Taraxaci Herba 10-35 parts, Gynostemmae Pentaphylli Herba 5-20 parts, Rhodiolae Roseae Radix 10-35 parts, Astragali Radix 10-30 parts, and stir-fried Atractylodis Macrocephalae Rhizoma 10-30 parts. The oral liquid prepared from the traditional Chinese medicine composition of the present invention can effectively treat mild and moderate rhinitis, has the effects of anti-allergy, immunosuppression, anti-inflammation and analgesia, has a relatively high total effective rate, and is not likely to relapse after drug withdrawal. At the same time, the present invention pays more attention to clearing and dispersing the lung qi, replenishing qi and strengthening the spleen, having supplementation in purgation, can regulate the body immunity, correct immune imbalance, and achieve the effect of treating both the symptoms and the root causes. The present invention has great medical value and broad application prospects in the field of treating rhinitis.

The application belongs to the technical field of microorganisms and particularly relates to application of heat-inactivated Bifidobacterium longum ZFML0012 in relieving rheumatoid arthritis. TNF-α 、 iNOS 、 IL-1β The mRNA expression level of the heat-inactivated Bifidobacterium longum ZFML0012 bacterial liquid can be lowered, and the mRNA expression level of the heat-inactivated Bifidobacterium longum ZFML0012 bacterial liquid can be raised. IL-10 The taxonomic name of the Bifidobacterium longum ZFML0012 is Bifidobacterium longum ( Bifidobacterium longum ) ZFML0012, and the preservation number is CCTCC NO: M 20252539. The heat-inactivated Bifidobacterium longum ZFML0012 bacterial liquid has anti-inflammatory activity on inflammation induced by lipopolysaccharide, and the heat-inactivated Bifidobacterium longum ZFML0012 bacterial liquid can improve joint injury and immune imbalance.

The invention discloses a pharmaceutical composition for improving myocardial injury by regulating autoimmunity and application, and relates to the technical field of biological medicines. The pharmaceutical composition for improving myocardial injury by adjusting autoimmunity comprises paeonol and pachymaran, the mass ratio of the paeonol to the pachymaran is (1-2): (1-2), and the invention further provides application of the pharmaceutical composition for improving myocardial injury by adjusting autoimmunity in preparation of drugs for treating myocardial injury. The traditional Chinese medicine composition can improve myocardial fibrosis, regulate CD4 + T cell immune balance and promote angiogenesis, and effectively solves the problems of poor myocardial repair effect after reperfusion injury after myocardial infarction and immune imbalance in a chronic inflammation stage after myocardial infarction.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of psoralen in the preparation of drugs for the prevention and treatment of rheumatoid arthritis. This invention aims to address the problem of insufficient efficacy and inadequate clinical needs of existing rheumatoid arthritis prevention and treatment drugs, filling the technological gap in the pharmacological activity of psoralen against rheumatoid arthritis. Studies have confirmed that psoralen can effectively inhibit the secretion of IL-6 and IL-8 by RA-FLS cells, effectively inhibit RA-FLS cell proliferation, migration, and invasion, significantly improve joint swelling and weight loss symptoms in CIA mice, effectively regulate immune imbalance, and effectively repair joint pathological damage. It blocks the pathological processes of rheumatoid arthritis, including inflammation, immune disorders, synovial damage, and bone destruction, from multiple pathways and dimensions. Furthermore, psoralen is a natural plant-derived component. This invention provides a novel natural drug option for the treatment of rheumatoid arthritis, effectively improving the existing treatment system for the disease.

The present invention relates to a synergistic bioactive pharmaceutical composition comprising Palmitoylethanolamide and Beta-glucan, along with pharmaceutically acceptable excipients, for improving respiratory health. It includes kits and formulations for preventing, managing or treating of respiratory disorders and conditions involving impaired respiratory function or immune imbalance.

This application discloses an application of a functional organ typing system based on human immune organoids in rheumatoid arthritis (RA), relating to the field of biomedical technology. This application develops a functional organ typing system based on human immune organoids. Using this model, the in vivo immune imbalance characteristics of RA are successfully reproduced. The in vitro state of T and B lymphocytes in RA patients is simulated, including germinal center formation, autoantibody secretion, inflammatory cytokine production, and immune cell interactions. Establishing such organoid models helps to more comprehensively elucidate the pathogenesis of rheumatoid arthritis and identify novel therapeutic targets associated with these immune cell populations.

The present application relates to the use of chicoric acid in the preparation of a medicament for preventing and / or treating myasthenia gravis. Specifically, the present application provides the use of chicoric acid and pharmaceutically acceptable salts, esters, solvates, polymorphs or prodrugs thereof in the preparation of a medicament for preventing and / or treating myasthenia gravis. The present application focuses on the use of the compound chicoric acid in correcting the core immune imbalance of myasthenia gravis, Th17 / Treg cell balance, intervening from the upstream of the disease, and is expected to achieve the fundamental treatment of myasthenia gravis and more persistent efficacy.

The invention discloses a ginsenoside composition and an application thereof, and particularly relates to an application of the ginsenoside composition in preparation of a medicine for treating asthma. The core of the composition is that the composition comprises the following components in specific parts by weight: 4-8 parts of ginsenoside Rg1 and 1-3 parts of ginsenoside Rb1, and 2-4 parts of total ginsenoside which takes effect together with one of the ginsenoside Rg1 and the ginsenoside Rb1 and is prepared through standardization, and the total content of the Rg1 and the Rb1 in the total ginsenoside is 50-70%. According to the present invention, the known pure saponin product and the standardized total saponin rich in the specific unknown saponin group are combined according to the specific ratio so as to produce the unexpected synergistic effect; pharmacodynamic experiments prove that the composition can significantly improve asthma symptoms and effectively inhibit airway inflammation, mucus hypersecretion and immune imbalance, and the curative effect of the composition is significantly superior to that of a single component or common total saponins. Meanwhile, the product quality is stable and controllable through a specific extraction and purification process.

The invention discloses a double-membrane independently wrapped nano drug delivery system for regulating macrophages and platelets. The nano drug delivery system comprises macrophage membrane coated nanoparticles and platelet membrane coated nanoparticles, the macrophage membrane coated nanoparticles are used for adjusting macrophage immune response and loaded with a Toll-like receptor 7 (TLR7) inhibitor, the platelet membrane coated nanoparticles are used for inhibiting abnormal activation of platelets and loaded with a G protein coupled receptor P2Y12 inhibitor, the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400, and the TLR7 inhibitor comprises at least one of TJ-M2010-5, hydroxychloroquine, Enpatron and IMO-8400. The P2Y12 inhibitor is prepared from at least one of ticagrelor, clopidogrel, prasugrel and cangrelor. According to the double-membrane independently-wrapped nano drug delivery system, drugs are efficiently delivered to related damaged cells of an inflammation part by utilizing related cell tropism of two cell membranes, immune disorder caused by macrophage and platelet abnormality is inhibited, diseases induced by immune imbalance are treated, an immune microenvironment is regulated and controlled, and the drug delivery effect is improved. And a new direction is provided for treatment of immune diseases.

The invention discloses a double natural drug loaded separable microneedle patch, which comprises a microneedle tip array layer prepared from a polylactic acid-glycolic acid copolymer loaded with rare ginsenoside Rk3 and diallyl trisulfide, and a separable backing layer connected to the back of the microneedle tip array layer, and the separable backing layer is prepared from polyvinyl alcohol and polyvinylpyrrolidone. In addition, the invention further discloses a preparation method and application of the separable microneedle patch loaded with the double natural drugs. According to the invention, Rk3 and DATS are cooperatively loaded in the PLGA microneedle, so that the effects of immunoregulation and angiogenesis promotion are exerted, the problems of local immune imbalance and tissue perfusion disorder in CLI treatment are remarkably improved, and anti-inflammatory and vascular remodeling dual-targeting combined treatment is realized.

The present invention relates to a novel Lactobacillus plantarum strain. In addition, the present invention relates to a composition for preventing, improving, or treating infertility or subfertility comprising the Lactobacillus plantarum strain.The Lactobacillus plantarum strain of the present invention reduces the expression of specific genes in cells constituting the placenta to help implantation of the embryo, increases the number of immune cells in the uterus, and enhances the implantation rate of embryos reduced by immune imbalance. Accordingly, it can be effectively utilized as a composition for the prevention, improvement, or treatment of infertility or subfertility.

The invention provides an electrical stimulation targeted drug delivery and closed-loop control method for sepsis immune regulation and control, and belongs to the technical field of automatic control systems.The electrical stimulation targeted drug delivery and closed-loop control method comprises the steps that immune index data of a patient is monitored in real time, abnormal analysis is conducted on the immune index data, and an inflammation unbalance coefficient is determined; outputting a corresponding electrical stimulation signal according to the inflammation imbalance coefficient; a micro-needle array sensor is adopted to detect local tissue impedance of a drug targeted delivery area, and the optimal administration dosage and administration frequency are generated; based on the optimal administration dosage and the administration frequency, controlling an electric control micropump to execute targeted administration, collecting real-time immune feedback data after administration, calculating an immune adjustment error, and adaptively adjusting electrical stimulation parameters to form closed-loop control; and repeating the above steps until the inflammation imbalance coefficient and the real-time immune feedback data reach a dynamic termination condition, and executing a regulation and control termination program to complete sepsis immune regulation and control. The regulation and control efficiency and safety of sepsis immune imbalance are obviously improved.

The application belongs to the technical field of biotechnology, and discloses an anti-human CD19 single-chain antibody and application. The anti-human CD19 single-chain antibody can be specifically combined with human CD19 protein and is stable in combination. By coupling the single-chain antibody with an adsorption column, B cells in blood can be adsorbed in a targeted manner, the level of pathogenic factors can be quickly reduced, and the abnormal activated or pathogenic B cells in circulation and the pathogenic factors such as antibodies, cytokines and the like generated by the B cells can be quickly reduced, so that the symptoms can be quickly relieved. The B cells can be relatively specifically removed, and the influence on other cells can be reduced. Time for other treatments is obtained, and in the acute attack or severe stage of the disease, the disease state can be stabilized, and favorable conditions for subsequent immune regulation treatment or other targeted treatment are created. The immune imbalance can be improved, and the imbalance state of the immune system can be adjusted, and the immune homeostasis can be recovered. The adsorption can be repeatedly performed as necessary to maintain the treatment effect, and the safety is high.